Researchers, Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. from the Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX. studied the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in men who have docetaxel-resistant hormone-refractory prostate cancer (HRPC). […]
Researchers at the Department of Urology, Centre Hospitalier Universitaire du Québec (CHUQ), Quebec, Canada evaluated the rate and duration of prostate-specific antigen (PSA) response to high-dose bicalutamide (150 mg) in men with non-metastatic castration-resistant prostate cancer (nmHRPC) as well as its impact on the duration of metastasis-free survival. They concluded that high dose bicalutamide is [...]
A small study of 145 men with asymptomatic metastatic hormone-refractory prostate cancer (HRPC) was conducted to determine the benefit of starting early chemotherapy with docetaxel. Collected data were analyzed from these subjects who were treated with chemotherapy between February 2000 and June 2002 in one French center. The men were categorized into three groups according [...]
The number of men with Hormone Refractory Prostate Cancer (HRCP) is ever increasing; some statisticians feel that it could eventually become the most common cancer in the male population. The clinical variability, the lack of consensus on patients' eligibility for starting a different treatment, and the response criteria seen in literature have made it difficult [...]
